Want to see HK:9966 full AI Analyst Report?
Alphamab Oncology (9966) Ratios
Alphamab Oncology Ratios
HK:9966's free cash flow for Q2 2026 was $-58.95M. For the 2026 fiscal year, HK:9966's free cash flow was decreased by $-5.93M and operating cash flow was $-53.03M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 5.67 | 6.74 | 5.84 | 3.88 | 3.32 |
| Quick Ratio | 5.29 | 6.41 | 5.55 | 3.71 | 3.23 |
| Cash Ratio | 0.92 | 4.38 | 4.07 | 2.78 | 1.26 |
| Solvency Ratio | -0.12 | 0.54 | -0.30 | -0.51 | -0.44 |
| Operating Cash Flow Ratio | -0.43 | 0.84 | -0.76 | -0.78 | -0.50 |
| Short-Term Operating Cash Flow Coverage | -3.64 | 4.06 | -2.70 | -1.72 | -0.71 |
| Net Current Asset Value | $ 1.21B | $ 1.30B | $ 1.09B | $ 934.67M | $ 1.28B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.06 | 0.08 | 0.12 | 0.16 | 0.24 |
| Debt-to-Equity Ratio | 0.07 | 0.10 | 0.15 | 0.22 | 0.34 |
| Debt-to-Capital Ratio | 0.07 | 0.09 | 0.13 | 0.18 | 0.25 |
| Long-Term Debt-to-Capital Ratio | 0.05 | 0.07 | 0.09 | 0.09 | 0.08 |
| Financial Leverage Ratio | 1.23 | 1.22 | 1.28 | 1.36 | 1.45 |
| Debt Service Coverage Ratio | -2.08 | 2.52 | -1.48 | -2.07 | -0.77 |
| Interest Coverage Ratio | -20.58 | 10.18 | -25.09 | -30.44 | -31.53 |
| Debt to Market Cap | 0.01 | 0.06 | 0.04 | 0.04 | 0.06 |
| Interest Debt Per Share | 0.14 | 0.20 | 0.28 | 0.39 | 0.70 |
| Net Debt to EBITDA | 1.60 | -5.91 | 6.41 | 1.85 | 0.46 |
| Profitability Margins | |||||
| Gross Profit Margin | 77.35% | 90.58% | 74.75% | 73.50% | 97.93% |
| EBIT Margin | -27.07% | 15.78% | -90.69% | -259.15% | -273.41% |
| EBITDA Margin | -15.35% | 24.50% | -59.10% | -234.85% | -245.26% |
| Operating Profit Margin | -27.07% | 15.78% | -139.66% | -259.15% | -284.63% |
| Pretax Profit Margin | -20.12% | 25.99% | -96.26% | -195.22% | -282.44% |
| Net Profit Margin | -20.12% | 25.99% | -96.26% | -195.22% | -282.44% |
| Continuous Operations Profit Margin | -20.12% | 25.99% | -96.26% | -195.22% | -282.44% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 74.33% | 164.68% | 68.92% | 75.33% | 99.23% |
| Return on Assets (ROA) | -5.29% | 7.42% | -9.85% | -15.38% | -15.25% |
| Return on Equity (ROE) | -6.48% | 9.08% | -12.59% | -20.91% | -22.05% |
| Return on Capital Employed (ROCE) | -8.22% | 5.08% | -16.34% | -24.95% | -20.10% |
| Return on Invested Capital (ROIC) | -8.06% | 4.95% | -15.66% | -22.53% | -16.80% |
| Return on Tangible Assets | -5.34% | 7.49% | -9.95% | -15.54% | -15.37% |
| Earnings Yield | -1.31% | 5.17% | -3.76% | -3.67% | -3.98% |
| Efficiency Ratios | |||||
| Receivables Turnover | 4.07 | 11.02 | 30.68 | 10.77 | 19.20 |
| Payables Turnover | 1.77 | 1.54 | 2.03 | 2.51 | 0.11 |
| Inventory Turnover | 1.16 | 0.74 | 0.70 | 0.68 | 0.05 |
| Fixed Asset Turnover | 1.16 | 1.26 | 0.39 | 0.27 | 0.28 |
| Asset Turnover | 0.26 | 0.29 | 0.10 | 0.08 | 0.05 |
| Working Capital Turnover Ratio | 0.40 | 0.47 | 0.18 | 0.13 | 0.09 |
| Cash Conversion Cycle | 198.83 | 290.83 | 352.76 | 422.03 | 3566.19 |
| Days of Sales Outstanding | 89.72 | 33.12 | 11.90 | 33.89 | 19.01 |
| Days of Inventory Outstanding | 315.25 | 495.06 | 520.35 | 533.67 | 6980.32 |
| Days of Payables Outstanding | 206.14 | 237.35 | 179.49 | 145.53 | 3433.15 |
| Operating Cycle | 404.97 | 528.18 | 532.25 | 567.56 | 6999.34 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.13 | 0.22 | -0.21 | -0.32 | -0.34 |
| Free Cash Flow Per Share | -0.16 | 0.19 | -0.25 | -0.46 | -0.51 |
| Dividend Paid and CapEx Coverage Ratio | -3.86 | 9.75 | -5.61 | -2.32 | -2.03 |
| Capital Expenditure Coverage Ratio | -3.86 | 9.75 | -5.61 | -2.32 | -2.03 |
| Operating Cash Flow Coverage Ratio | -0.99 | 1.14 | -0.79 | -0.87 | -0.50 |
| Operating Cash Flow to Sales Ratio | -0.22 | 0.33 | -0.93 | -1.80 | -2.20 |
| Free Cash Flow Yield | -1.81% | 5.92% | -4.27% | -4.84% | -4.62% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -73.35 | 19.34 | -26.60 | -27.25 | -25.12 |
| Price-to-Sales (P/S) Ratio | 15.34 | 5.03 | 25.60 | 53.19 | 70.96 |
| Price-to-Book (P/B) Ratio | 4.94 | 1.76 | 3.35 | 5.70 | 5.54 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -55.14 | 16.88 | -23.43 | -20.64 | -21.64 |
| Price-to-Operating Cash Flow Ratio | -69.43 | 15.15 | -27.61 | -29.55 | -32.32 |
| Price-to-Earnings Growth (PEG) Ratio | 0.43 | -0.11 | 0.72 | 1.33 | 5.78 |
| Enterprise Value Multiple | -98.38 | 14.61 | -36.91 | -20.80 | -28.47 |
| Enterprise Value | 8.33B | 2.29B | 4.77B | 8.15B | 10.20B |
| EV to EBITDA | -98.38 | 14.61 | -36.91 | -20.80 | -28.47 |
| EV to Sales | 15.10 | 3.58 | 21.81 | 48.85 | 69.82 |
| EV to Free Cash Flow | -54.25 | 12.02 | -19.97 | -18.96 | -21.30 |
| EV to Operating Cash Flow | -68.31 | 10.79 | -23.53 | -27.14 | -31.80 |
| Tangible Book Value Per Share | 1.76 | 1.85 | 1.72 | 1.65 | 1.98 |
| Shareholders’ Equity Per Share | 1.78 | 1.87 | 1.74 | 1.67 | 2.00 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.57 | 0.65 | 0.23 | 0.18 | 0.16 |
| Net Income Per Share | -0.12 | 0.17 | -0.22 | -0.35 | -0.44 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 0.74 | 1.65 | 1.06 | 0.75 | 1.03 |
| Research & Development to Revenue | 0.90 | 0.63 | 1.86 | 2.81 | 3.30 |
| SG&A to Revenue | 0.15 | 0.12 | 0.36 | 0.52 | 0.53 |
| Stock-Based Compensation to Revenue | 0.03 | 0.00 | 0.06 | 0.08 | 0.06 |
| Income Quality | 1.07 | 1.28 | 0.96 | 0.92 | 0.78 |
Currency in CNY
